Navigation Links
Sosei Confirms the Safety of SD118 in Two Phase I Trials
Date:12/8/2008

TOKYO, December 8 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the successful results of two Phase I trials for its collaborative project on SD118, a compound in development for the treatment of neuropathic pain.

SD118 is being jointly developed with NeuroDiscovery Ltd (ASX Code: NDL) and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication. Now, following animal model studies conducted in Sosei's Drug Reprofiling Platform (DRP), it has demonstrated potential as a new oral neuropathic pain therapy.

The Phase I trials were both double-blind, placebo-controlled, dose escalation studies designed to evaluate the safety, tolerability and pharmacokinetics of SD118 administered in an oral formulation.

In the first trial, a single ascending dose (SAD) study conducted in 56 healthy male volunteers, no serious adverse events (SAEs) were reported in any of dose ranges including the highest dose used in the study. Notably, the plasma concentration of SD118 increased proportionately with administered doses of the drug across the entire dose range investigated. Consequently, SD118 was considered to be safe and well tolerated in doses up to 2000mg.

In the second trial, a multiple ascending dose (MAD) study conducted in 36 healthy male volunteers, no SAEs were reported and SD118 was considered safe and well tolerated. At the maximum dose of 2,000mg BID, nervous system related adverse events were reported, paraesthesia by four subjects, and hypoaesthesia by one subject, but there were no concerns regarding clinical safety. In this study the pharmacokinetic profile also showed a plasma concentration increase in proportion to doses of SD118 from 100mg BID to 2,000mg BID.

Mr Shinich
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
2. Sosei Announces Completion of Phase III Trial for NorLevo(R)
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
6. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
7. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
8. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
9. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
10. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... TLC Vision announced today its plans for opening a ... Diego.  Internationally recognized as leaders in field of refractive surgery, ... will lend their surgical skill and expertise to the TLC ... continue to be at the forefront of working with optometry ...
... Kaiser Permanente,s National Pharmacy Programs and Services was recognized at ... Vegas as a J.D. Power 2011 Customer Service Champion ... the distinction this year. To qualify for ... within their own industries, but also must stand out among ...
Cached Medicine Technology:TLC Vision Announces TLC Laser Eye Center San Diego 2Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids to ... now being treated at Florida Hospital Tampa with the device that provides direct, ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a multidisciplinary ... website at Healthpointe.net. The new website will feature a sleek and streamlined design ... to provide smoother interactions between patients and the Healthpointe clinics and ensures that ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... MI (PRWEB) , ... July 31, 2015 , ... ... Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced all over ... Eilers, explains that “With considerable effort, we have developed the highest-quality oils in ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... , , , ... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported financial results for ... $209.4 million for the quarter ended June 30, 2009, which includes net ... million associated with the Company,s sales force reduction in the second quarter, ...
... Wednesday, August 5, 2009, ... 9:00 a.m. EDT, ... 1-800-731-5774, ... to participate in a briefing on Wednesday, August 5, with David B. Holtz, Interim President Chief Executive ...
... , MEQUON, Wis., July 21 Wonderbox ... its clients to benefit from continued advances in technology and ... Management Module designed for managed care benefit administration and case ... tools for scheduling, managing, and monitoring day-to-day care tasks and ...
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... Mich., July 21 The Michigan Chamber of Commerce ... health care reform and urged Michigan,s Congressional Delegation to demand ... , , "Like the U.S. ... and the President to reform the health care system for ...
... , , OWINGS MILLS, Md., ... leading portion-controlled weight-loss program, today announced the launch of Honey Mustard ... and Parmesan Cheese Puffs. The new pretzel sticks and cheese puffs ... & 1 Plan, while also maintaining the nutritional value of Medifast ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Michigan Chamber of Commerce Raises Concerns With Flawed Federal Health Care Reform Proposal, Rushed Timeline 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 3